|Expert opinion on therapeutic targets (2007) 11:695-705|
|Northeast Structural Genomics Consortium|
(click to unfold)
Nicotinamide adenine dinucleotide (NAD(+)) has crucial roles in many cellular processes, both as a coenzyme for redox reactions and as a substrate to donate ADP-ribose units. ...
Enzymes involved in NAD(+) metabolism are attractive targets for drug discovery against a variety of human diseases, including cancer, multiple sclerosis, neurodegeneration and Huntington's disease. A small-molecule inhibitor of nicotinamide phosphoribosyltransferase, an enzyme in the salvage pathway of NAD(+) biosynthesis, is presently in clinical trials against cancer. An analog of a kynurenine pathway intermediate is efficacious against multiple sclerosis in an animal model. Indoleamine 2,3-dioxygenase plays an important role in immune evasion by cancer cells and other disease processes. Inhibitors against kynurenine 3-hydroxylase can reduce the production of neurotoxic metabolites while increasing the production of neuroprotective compounds. This review summarizes the existing knowledge on NAD(+) metabolic enzymes, with emphasis on their relevance for drug discovery.
|drug therapy antagonists & inhibitors metabolism pharmacology therapeutic use physiology drug effects |
|DNA Damage Signal Transduction Clinical Trials, Phase II as Topic Kynurenine Piperidines Tryptophan Acrylamides Neoplasms Neuroprotective Agents Mice Neurodegenerative Diseases Aging Autoimmune Diseases Poly Adenosine Diphosphate Ribose Sirtuins Drug Design NAD Humans Enzyme Inhibitors Adenosine Diphosphate Ribose Animals Cyclic ADP-Ribose Antineoplastic Agents |
|93 (Last update: 04/01/2017 11:29:55am)|